title: Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
abstract: OBJECTIVE
  To investigate whether idarubicin in a cytarabine-based induction regimen was superior to daunorubicin in de novo acute myeloid leukemia patients expressing high MDR1.
  
  
  METHODS
  The clinicopathological data were analyzed in 125 patients receiving daunorubicin or idarubicin with cytarabine for remission induction. Median MDR1 mRNA expression in pretreated bone marrow cells was used as the cutoff point for high and low MDR1 expression.
  
  
  RESULTS
  A total of 59.7% high and 77.8% low MDR1 expressers achieved complete remission (CR; p = 0.029). Idarubicin yielded a higher CR rate than daunorubicin in high MDR1 expressers (82.1 vs 41.2%; p = 0.001), it also demonstrated a higher CR rate than daunorubicin (p < 0.05) in high MDR1 expressers exhibiting favorable or intermediate risk, while there was no difference between the two treatment arms in low MDR1 expressers exhibiting either favorable or intermediate risk.
  
  
  CONCLUSIONS
  Idarubicin is associated with better remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
authors.affiliation: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: Pengcheng
authors.initials: P
authors.lastname: Shi
authors.forename: Jie
authors.initials: J
authors.lastname: Zha
authors.forename: Xutao
authors.initials: X
authors.lastname: Guo
authors.forename: Feili
authors.initials: F
authors.lastname: Chen
authors.forename: Zhiping
authors.initials: Z
authors.lastname: Fan
authors.forename: Fen
authors.initials: F
authors.lastname: Huang
authors.forename: Fanyi
authors.initials: F
authors.lastname: Meng
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Liu
authors.forename: Ru
authors.initials: R
authors.lastname: Feng
authors.forename: Bing
authors.initials: B
authors.lastname: Xu
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D012333:RNA, Messenger; D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin